Bryce Point Capital LLC Takes $901,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Bryce Point Capital LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 37,272 shares of the company's stock, valued at approximately $901,000.

Other institutional investors also recently bought and sold shares of the company. Main Management ETF Advisors LLC purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $672,000. Means Investment CO. Inc. increased its position in Hims & Hers Health by 23.5% during the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock valued at $1,210,000 after buying an additional 9,508 shares in the last quarter. Principal Financial Group Inc. raised its stake in Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock valued at $5,349,000 after buying an additional 146,621 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in Hims & Hers Health in the fourth quarter worth about $2,628,000. Finally, Pacer Advisors Inc. purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $374,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Down 0.6 %

Shares of NYSE HIMS traded down $0.17 during midday trading on Tuesday, reaching $27.60. 11,741,637 shares of the stock were exchanged, compared to its average volume of 14,744,908. The firm has a market cap of $6.13 billion, a price-to-earnings ratio of 62.71 and a beta of 1.65. The firm has a 50-day simple moving average of $39.76 and a two-hundred day simple moving average of $30.11. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to analysts' expectations of $494.56 million. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the transaction, the chief executive officer now owns 97,687 shares in the company, valued at $5,692,221.49. This represents a 56.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $29.26, for a total transaction of $338,860.06. Following the completion of the transaction, the chief financial officer now directly owns 124,104 shares in the company, valued at $3,631,283.04. This represents a 8.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 809,806 shares of company stock worth $30,923,658 over the last three months. 17.71% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

HIMS has been the subject of a number of recent analyst reports. Morgan Stanley cut shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their target price for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Piper Sandler raised their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Bank of America boosted their price target on Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research note on Tuesday, March 18th. Finally, Leerink Partners raised their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $37.31.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.